Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherBasic Science (Animal or Phantoms)

18F-5-fluoro-aminosuberic acid (FASu) as a potential tracer to gauge oxidative stress in breast cancer models

Hua Yang, Silvia Jenni, Milena Colovic, Helen Merkens, Carlee Poleschuk, Isabel Rodrigo, Qing Miao, Bruce F Johnson, Michael J Rishel, Vesna Sossi, Jack M. Webster, François Bénard and Paul Schaffer
Journal of Nuclear Medicine October 2016, jnumed.116.180661; DOI: https://doi.org/10.2967/jnumed.116.180661
Hua Yang
1 TRIUMF, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Silvia Jenni
2 British Columbia Cancer Agency, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Milena Colovic
1 TRIUMF, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helen Merkens
3 British Columabia Cancer Agency, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlee Poleschuk
1 TRIUMF, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isabel Rodrigo
1 TRIUMF, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qing Miao
1 TRIUMF, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruce F Johnson
4 GE Global Research, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J Rishel
4 GE Global Research, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vesna Sossi
5 University of British Columbia, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jack M. Webster
4 GE Global Research, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
François Bénard
2 British Columbia Cancer Agency, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Schaffer
1 TRIUMF, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Abstract

The cystine transporter (system xC-) is an antiporter of cystine and glutamate. It has relatively low basal expression in most tissues and becomes upregulated in cells under oxidative stress (OS) as one of the genes expressed in response to the antioxidant response element (ARE) promoter. We have developed 18F-5-fluoro-aminosuberic acid (FASu), a Positron Emission Tomography (PET) tracer that targets system xC-. The goal of this study was to evaluate the suitability of 18F-FASu as a specific gauge for system xC- activity in vivo and its potential usefulness for breast cancer imaging. Methods: 18F-FASu specificity towards system xC- was studied by cell inhibition assay, cellular uptake following OS induction with diethyl maleate (DEM), with and without anti-xCT siRNA knockdown, in vitro uptake studies and in vivo uptake in a system xC- transduced xenograft model. In addition, radiotracer uptake was evaluated in three separate breast cancer models MDA-MB-231, MCF-7 and ZR-75-1. Results: Reactive oxygen species (ROS)-inducing DEM increased glutathione level and 18F-FASu uptake, while gene knocking down with anti-xCT siRNA led to decreased tracer uptake. 18F-FASu uptake was robustly inhibited by system xC- inhibitors or substrates, while the uptake was significantly higher in transduced cells and tumors expressing xCT compared to the wild type HEK293T cells and tumors (p<0.0001 for cells, P = 0.0086 for tumors). The 18F-FASu demonstrated tumor uptake in all three breast cancer cell lines studied. Among them, triple negative breast cancer MDA-MB-231 had the highest tracer uptake (P = 0.0058 when compared with MCF-7; p<0.0001 when compared with ZR-75-1), which also has the highest xCT mRNA level. Conclusion: 18F-FASu as a system xC- substrate is a specific PET tracer for functional monitoring of system xC- and OS imaging. By enabling non-invasive analysis of xC- responses in vivo, this biomarker may serve as a valuable target for the diagnosis and treatment monitoring of certain breast cancers.

  • Molecular Imaging
  • PET
  • Radiopharmaceuticals
  • F-18
  • Oxidative Stress
  • PET
  • System xC-
  • tumor imaging
  • Copyright © 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Next
Back to top

In this issue

Journal of Nuclear Medicine: 66 (6)
Journal of Nuclear Medicine
Vol. 66, Issue 6
June 1, 2025
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
18F-5-fluoro-aminosuberic acid (FASu) as a potential tracer to gauge oxidative stress in breast cancer models
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
18F-5-fluoro-aminosuberic acid (FASu) as a potential tracer to gauge oxidative stress in breast cancer models
Hua Yang, Silvia Jenni, Milena Colovic, Helen Merkens, Carlee Poleschuk, Isabel Rodrigo, Qing Miao, Bruce F Johnson, Michael J Rishel, Vesna Sossi, Jack M. Webster, François Bénard, Paul Schaffer
Journal of Nuclear Medicine Oct 2016, jnumed.116.180661; DOI: 10.2967/jnumed.116.180661

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
18F-5-fluoro-aminosuberic acid (FASu) as a potential tracer to gauge oxidative stress in breast cancer models
Hua Yang, Silvia Jenni, Milena Colovic, Helen Merkens, Carlee Poleschuk, Isabel Rodrigo, Qing Miao, Bruce F Johnson, Michael J Rishel, Vesna Sossi, Jack M. Webster, François Bénard, Paul Schaffer
Journal of Nuclear Medicine Oct 2016, jnumed.116.180661; DOI: 10.2967/jnumed.116.180661
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Comparative Evaluation of [18F]5-Fluoroaminosuberic Acid and (4S)-4-3-[18F]fluoropropyl)-L-Glutamate as System Formula-Targeting Radiopharmaceuticals
  • Comparative Evaluation of [18F]5-Fluoroaminosuberic Acid and (4S)-4-3-[18F]fluoropropyl)-L-Glutamate as System Formula-Targeting Radiopharmaceuticals
  • Clinical Evaluation of (4S)-4-(3-[18F]Fluoropropyl)-L-glutamate (18F-FSPG) for PET/CT Imaging in Patients with Newly Diagnosed and Recurrent Prostate Cancer
  • The Characterization of 18F-hGTS13 for Molecular Imaging of xC- Transporter Activity with PET
  • Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance
  • Assessment of Tumor Redox Status through (S)-4-(3-[18F]fluoropropyl)-L-Glutamic Acid PET Imaging of System xc- Activity
  • Google Scholar

Similar Articles

Keywords

  • molecular imaging
  • PET
  • radiopharmaceuticals
  • F-18
  • oxidative stress
  • System xC-
  • tumor imaging
SNMMI

© 2025 SNMMI

Powered by HighWire